Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Uyl-de Groot

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
European Journal of Haematology|January 19, 2005
Health related quality of life in patients with multiple myeloma undergoing a double transplantationC A Uyl-de Groot, I Buijt, I J M Gloudemans, et al.
Nederlands Tijdschrift Voor Geneeskunde|August 12, 2003
[Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ]M T Groot, G J Ossenkoppele, M H Kramer, et al.
The Netherlands Journal of Medicine|May 16, 2014
Access to expensive cancer drugs in Dutch daily practice: should we be concerned?H M Blommestein, M G Franken, S G R Verelst, et al.
European Journal of Cancer (Oxford, England : 1990)|April 28, 2004
A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III studyM van Agthoven, C M Segeren, I Buijt, et al.
Annals of Hematology|August 7, 2012
Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre studyH M Blommestein, S G R Verelst, P C Huijgens, et al.
Journal of Clinical Pharmacy and Therapeutics|November 7, 2012
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agentsJ G Gaultney, M G Franken, S S Tan, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|June 20, 2014
Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neckN van der Linden, C W M van Gils, C P Pescott, et al.
Plos One|May 23, 2017
Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatmentsS De Groot, H M Blommestein, W K Redekop, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 17, 2017
Health-related quality of life and its determinants in patients with metastatic renal cell carcinomaS de Groot, W K Redekop, M M Versteegh, et al.
American Journal of Rhinology|September 14, 2001
Quality of life of patients with refractory chronic rhinosinusitis: effects of filgrastim treatmentM van Agthoven, W J Fokkens, J P van de Merwe, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
European Journal of Haematology|January 19, 2005
Health related quality of life in patients with multiple myeloma undergoing a double transplantationC A Uyl-de Groot, I Buijt, I J M Gloudemans, et al.
Nederlands Tijdschrift Voor Geneeskunde|August 12, 2003
[Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ]M T Groot, G J Ossenkoppele, M H Kramer, et al.
The Netherlands Journal of Medicine|May 16, 2014
Access to expensive cancer drugs in Dutch daily practice: should we be concerned?H M Blommestein, M G Franken, S G R Verelst, et al.
European Journal of Cancer (Oxford, England : 1990)|April 28, 2004
A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III studyM van Agthoven, C M Segeren, I Buijt, et al.
Annals of Hematology|August 7, 2012
Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre studyH M Blommestein, S G R Verelst, P C Huijgens, et al.
Journal of Clinical Pharmacy and Therapeutics|November 7, 2012
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agentsJ G Gaultney, M G Franken, S S Tan, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|June 20, 2014
Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neckN van der Linden, C W M van Gils, C P Pescott, et al.
Plos One|May 23, 2017
Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatmentsS De Groot, H M Blommestein, W K Redekop, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 17, 2017
Health-related quality of life and its determinants in patients with metastatic renal cell carcinomaS de Groot, W K Redekop, M M Versteegh, et al.
American Journal of Rhinology|September 14, 2001
Quality of life of patients with refractory chronic rhinosinusitis: effects of filgrastim treatmentM van Agthoven, W J Fokkens, J P van de Merwe, et al.
Pageof 7